Imagine testing a new medicine by watching a tiny heart cell's electrical beat and its physical structure at the same time for weeks. Instead of relying on animal tests that often fail, this tool uses lasers and imaging to spot red flags early. It's like having a high-definition security camera and a heart monitor combined for a single cell.
Drug development is hindered by high attrition rates due to cardiac adverse effects. Current in-vitro tests are short-term and cannot simultaneously measure both electrical and structural damage, leading to reliance on animal tests that fail to predict human outcomes.
A multiparametric in-vitro platform that combines action potential recordings with live-cell fluorescence imaging for chronic cardiotoxicity assessment.
If you are a drug discovery firm dealing with high attrition rates in clinical trials — this project developed a platform that assesses functional and structural cardiotoxicity simultaneously. This allows you to identify unsafe compounds before the earliest clinical trial phase.
If you are a pre-clinical research lab dealing with the inefficiency of animal models where 9/10 drugs fail in human trials — this project developed a tool for chronic toxicity assessment over more than 1 month. This reduces the reliance on rodent and non-rodent species tests.
If you are a CRO dealing with the need for more reliable safety predictions — this project developed a combined electrophysiology and fluorescence imaging platform. This enables you to offer multiparametric toxicity screening to your clients.
Based on available project data, specific pricing or cost details for the platform are not provided.
The project aims for the commercialization of a platform to reshape the in-vitro cardiotoxicity market, suggesting an intent for industrial scale, though specific throughput numbers are not listed.
The platform is based on the unique laser-based technology of Foresee Biosystems, but specific licensing terms are not mentioned in the report.
The project leverages the FDA Modernization Act, which pushes for the translation of in-vitro methods to improve safety predictions and reduce animal testing.
The platform is designed for extremely long tests lasting more than 1 month to enable the assessment of chronic toxic effects.
The project is led by a single Italian SME, Foresee Biosystems SRL, with a 100% industry ratio. This lean structure indicates a direct path to commercialization without the typical delays of academic-industrial transfers, as the coordinator is the sole developer and intended seller of the technology.
Contact Foresee Biosystems SRL in Italy for commercial inquiries regarding the SiMulTox platform.
Contact us to find similar high-throughput toxicity screening technologies.
